X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1217) 1217
index medicus (1014) 1014
hepatitis b (848) 848
male (697) 697
female (679) 679
hepatitis b virus (678) 678
gastroenterology & hepatology (607) 607
middle aged (557) 557
adult (551) 551
hbv (549) 549
hepatitis (461) 461
hepatitis b virus - genetics (431) 431
health aspects (391) 391
infection (373) 373
antiviral agents - therapeutic use (350) 350
hbv reactivation (344) 344
virology (331) 331
surface-antigen (315) 315
lamivudine (306) 306
aged (291) 291
hepatitis b surface antigens - blood (279) 279
chemotherapy (278) 278
hepatocellular-carcinoma (278) 278
dna, viral - blood (273) 273
reactivation (257) 257
hepatitis b virus - immunology (254) 254
risk factors (254) 254
hepatitis b - virology (252) 252
therapy (238) 238
liver (233) 233
dna (232) 232
hepatitis b virus - physiology (226) 226
infectious diseases (219) 219
antiviral agents (214) 214
hbv infection (206) 206
virus diseases (204) 204
digestive system diseases (201) 201
hepatitis b, chronic - drug therapy (196) 196
infections (194) 194
antigens (190) 190
mutation (188) 188
hepatitis b, chronic - virology (183) 183
risk (182) 182
prevalence (179) 179
hepatitis b - drug therapy (176) 176
cancer (174) 174
deoxyribonucleic acid--dna (173) 173
care and treatment (172) 172
hepatitis b virus - isolation & purification (171) 171
analysis (170) 170
treatment outcome (170) 170
hepatitis b - complications (165) 165
hbsag (164) 164
hepatitis b virus - drug effects (164) 164
young adult (164) 164
hepatitis b - epidemiology (163) 163
interferon (162) 162
hepatitis b antibodies - blood (161) 161
hepatitis b surface antigen (160) 160
natural-history (160) 160
viral load (160) 160
oncology (159) 159
genotype (156) 156
hepatitis b - immunology (155) 155
adolescent (154) 154
hbv dna (153) 153
hepatitis b - diagnosis (153) 153
retrospective studies (152) 152
transplantation (148) 148
medicine & public health (146) 146
virus activation - drug effects (146) 146
prevention (142) 142
hepatocellular carcinoma (140) 140
immunology (140) 140
management (139) 139
hepatitis-b-virus (137) 137
virus-infection (135) 135
viruses (134) 134
lamivudine - therapeutic use (132) 132
rituximab (130) 130
gastroenterology and hepatology (128) 128
hepatology (128) 128
hcv (125) 125
replication (125) 125
hepatitis b - prevention & control (124) 124
virus activation (124) 124
cytotoxic chemotherapy (122) 122
hiv (122) 122
hepatitis b, chronic - immunology (120) 120
prophylaxis (119) 119
research (119) 119
chronic hepatitis b (116) 116
cirrhosis (114) 114
vaccination (112) 112
hepatitis c virus (111) 111
dna, viral - genetics (110) 110
drug therapy (109) 109
liver cancer (109) 109
entecavir (108) 108
liver cirrhosis (108) 108
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1811) 1811
Japanese (50) 50
French (18) 18
Korean (12) 12
Spanish (12) 12
German (9) 9
Chinese (5) 5
Polish (3) 3
Hungarian (2) 2
Turkish (2) 2
Italian (1) 1
Portuguese (1) 1
Russian (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Hepatology, ISSN 0270-9139, 05/2009, Volume 49, Issue S5, pp. S156 - S165
Journal Article
JAMA, ISSN 0098-7484, 12/2014, Volume 312, Issue 23, pp. 2521 - 2530
IMPORTANCE: Hepatitis B virus (HBV) reactivation is a serious complication for patients with lymphoma treated with rituximab-containing chemotherapies, despite... 
PROPHYLACTIC LAMIVUDINE | CYTOTOXIC CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | SEROPOSITIVE CANCER-PATIENTS | HBV REACTIVATION | PREEMPTIVE LAMIVUDINE | PLUS RITUXIMAB | NON-HODGKINS-LYMPHOMA | HIGH PREVALENCE | ELDERLY-PATIENTS | DES-LYMPHOMES | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Guanine - analogs & derivatives | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Hepatitis B Surface Antigens - blood | Lamivudine - adverse effects | Young Adult | Lamivudine - therapeutic use | Vincristine - administration & dosage | Adult | Female | Guanine - adverse effects | Hepatitis B virus - immunology | Guanine - therapeutic use | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Antiviral Agents - therapeutic use | Rituximab | Lymphoma, Large B-Cell, Diffuse - virology | Hepatitis B - etiology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antiviral Agents - adverse effects | Aged | Hepatitis B - prevention & control | Antibodies, Monoclonal, Murine-Derived - adverse effects | Clinical trials | Hepatitis | Chemotherapy | Lymphomas | Antiviral drugs
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 6, pp. 1297 - 1309
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2015, Volume 61, Issue 5, pp. 719 - 729
Journal Article
Hepatology, ISSN 0270-9139, 08/2017, Volume 66, Issue 2, pp. 379 - 388
Journal Article
Cancer, ISSN 0008-543X, 09/2017, Volume 123, Issue 18, pp. 3540 - 3549
BACKGROUND Chemotherapy, target therapy, and immunotherapy are increasingly being used in the systematic treatment of nasopharyngeal carcinoma (NPC), during... 
antiviral prophylaxis | reactivation | nasopharyngeal carcinoma | screening | hepatitis B virus | RISK-FACTORS | RECEIVING CYTOTOXIC CHEMOTHERAPY | SOLID TUMORS | RANDOMIZED CONTROLLED-TRIAL | BREAST-CANCER | LAMIVUDINE | CANCER-PATIENTS | HBV REACTIVATION | ONCOLOGY | INFECTION | CONCURRENT CHEMORADIOTHERAPY | Multivariate Analysis | Age Distribution | Hepatitis B virus - pathogenicity | Humans | Middle Aged | Male | Hepatitis B, Chronic - diagnosis | Mass Screening - methods | Incidence | Endemic Diseases | Young Adult | Carcinoma - epidemiology | Adult | Female | Retrospective Studies | Nasopharyngeal Neoplasms - diagnosis | Virus Activation | Databases, Factual | Nasopharyngeal Carcinoma | Risk Assessment | Comorbidity | Hepatitis B, Chronic - epidemiology | Nasopharyngeal Neoplasms - therapy | Carcinoma - diagnosis | Logistic Models | China - epidemiology | Antiviral Agents - administration & dosage | Hepatitis B, Chronic - drug therapy | Nasopharyngeal Neoplasms - epidemiology | Adolescent | Sex Distribution | Carcinoma - therapy | Aged | Intelligence | Liver | Prophylaxis | Viruses | Infections | Activation | Cancer therapies | Risk factors | Immunosuppressive agents | Metastases | Nasopharyngeal carcinoma | Hepatitis | Data management | Immunotherapy | Hepatitis B virus | Deoxyribonucleic acid--DNA | Monitoring | Enzymes | Risk groups | Health risks | Data processing | Risk analysis | Patients | Screening | Chemotherapy | Health risk assessment | Hepatitis B | Cancer
Journal Article